Search

Nature Biotechnology's annual survey highlights academic start ups that are, among other things, correcting misfolded or disordered proteins, creating second-generation GPCR agonists, building a new gene delivery platform and mining cancer genomes for novel targets. [ABSTRACT FROM AUTHOR]

A group of experts reflects on what was learned from the first human transplants of genetically engineered pig organs and what the future of xenotransplantation may hold. [ABSTRACT FROM AUTHOR]

Nature Biotechnology's annual survey highlights academic startups that are, among other things, designing circular RNA therapeutics, tackling cancer with arenaviruses, creating psychedelics without the trip, editing genes and cells in vivo, harnessing the power of autoantibodies and editing the epigenome. [ABSTRACT FROM AUTHOR]

Despite its checkered reputation, cryptocurrency is being considered by a handful of academics as a means to funnel funds into translational research. Is the trend likely to spread? Laura DeFrancesco and Ariel Klevecz investigate. [ABSTRACT FROM AUTHOR]

Whether pan-vaccines or antibodies, SARS-CoV-2 is adding impetus to the race for broad-spectrum countermeasures against the world's next infectious scourges. [ABSTRACT FROM AUTHOR]

Even though only a few labs around the world have the means to engineer a purely synthetic virus, debate on the origins of SARS-CoV-2 has resurfaced concerns about the risks and benefits of synthetic virology. [ABSTRACT FROM AUTHOR]

Nature Biotechnology's annual survey highlights university startups that are, among other things, rethinking how to deliver gene-editing therapy and tackling various metabolic conditions, immune disorders and cancer with microbiome treatments or immunotherapy. Michael Eisenstein, Ken Garber, Esther Landhuis, Caroline Seydel and Laura DeFrancesco report. [ABSTRACT FROM AUTHOR]

With the first readouts of trials of antibodies against COVID-19 appearing and others coming thick and fast, Nature Biotechnology asked a group of experts to comment on the challenges and timelines for these products. [ABSTRACT FROM AUTHOR]

Nature Biotechnology convenes a group of experts to provide their insights into SARS-CoV-2 vaccines in development. [ABSTRACT FROM AUTHOR]

The Chan Zuckerberg Biohub is both an institute and an academic network devoted to accelerating research via cutting edge technologies and open science. Its focus on single-cell analysis and infectious disease has placed it front and center in the pandemic. [ABSTRACT FROM AUTHOR]

Capturing the value back from plastic waste has been the holy grail of recyclers. Biotechnology is taking us closer to a solution. [ABSTRACT FROM AUTHOR]

Our annual survey highlights startups tackling intractable viruses with new vaccine design, engineering a reliable source of platelets, universalizing cell therapies, improving cancer screening, developing RNA-editing platforms and targeting protein–RNA interactions. Michael Eisenstein, Ken Garber, Caroline Seydel and Laura DeFrancesco report. [ABSTRACT FROM AUTHOR]

In one year, George Church's group spun out 16 different startups. What explains the lab's incredible output of entrepreneurs? [ABSTRACT FROM AUTHOR]

Millions of people each year are giving up their genotype information for research, for health, for fun and now for profit. [ABSTRACT FROM AUTHOR]

A cadre of new biotechs have set their sights on targeting RNA with small-molecule drugs. Justin Petrone and Laura DeFrancesco report. [ABSTRACT FROM AUTHOR]

The article presents several short overviews of the science and technology chosen by the editors in 2014's crop of startups, which focuses on drug testing or therapies against rare disease, cancer, gastrointestinal disease, fibrosis and pain. Included topics are unum therapeutics as a universal cellular immunotherapy, voyager therapeutics and lysogene, and turning CRISPRs into drugs.

The article focuses on efforts of research and development industry for advances in technology and science to increase chances of developing anti-aging interventions. It mentions the evolving concept of aging which is focusing on longevity that is to extend the period of healthy life by slowing the biological process of aging. It reports the pathways contributing to longevity based on model systems which include insulin signaling, role of sirtuins and mammalian target of rapamycin (mTOR).

Nat. Biotechnol. 36, 297–306 (2018); published online 5 April 2018; corrected after print 15 May 2018 In the version of this article initially published, the name and photo of Viviane Tabar, one of BlueRock's founders, was omitted. A misplaced '&' in the author list in the PDF has been corrected, and the abbreviation MSKCC added in the text. [ABSTRACT FROM AUTHOR]

The article focuses on developments related to confidential business information (CBI) in the biotechnology and pharmaceutical industries as of June 2014. Topics highlighted include efforts of researchers, government regulators and companies to redefine what CBI is, increase in criticism of the industries' data disclosure practices and legal protection of trade secrets. Also discussed is the industries' protection of human data related to safety and efficacy of drugs.

The article focuses on research topics related to science and technology performed by several healthcare companies including XO1, Solstice Biologics and Arvinas. Topics discussed include protein homeostasis in drug discovery, development of disease resistance traits through plant microbiome and the use of RNA interference based drug. Also mentions the gene therapy of eye.